2-acetamido-2-deoxy-D-galactopyranosyluronic acid | 4713-64-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-acetamido-2-deoxy-D-galactopyranosyluronic acid
• 英文别名: 2-acetamido-2-deoxy-D-galacturonic acid；N-Acetylchondrosinat；2-Acetamido-2-deoxy-D-galactopyranuronic acid；(2S,3R,4R,5R)-5-acetamido-3,4,6-trihydroxyoxane-2-carboxylic acid
• CAS: 4713-64-8；90319-06-5
• 化学式: C₈H₁₃NO₇
• 分子量: 235.194
• InChiKey: KSOXQRPSZKLEOR-YIDMHZNGSA-N

物化性质

• 沸点：
  679.2±55.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  136
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  methyl 1,3,4-tri-O-acetyl-2-azido-2-deoxy-α-D-galacturonate 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 生成 2-acetamido-2-deoxy-D-galactopyranosyluronic acid
  参考文献：
  名称：

  Synthesis of 2-acetamido-2-deoxyhexuronic acids with the d-gluco, d-manno, and d-galacto configurations

  摘要：

  DOI：

  10.1016/s0008-6215(82)80021-9

文献信息

• Vaccines and compositions for the prevention of Salmonella infections
  申请人：Bharat Biotech International Limited

  公开号：US10576138B2

  公开（公告）日：2020-03-03

  Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.

  本发明公开了用于预防伤寒沙门氏菌的稳定共轭疫苗制剂，以及将伤寒沙门氏菌的Vi-多糖与作为载体蛋白的破伤风类毒素共轭的方法，这些方法可产生针对伤寒沙门氏菌引起的伤寒的更好的T依赖性免疫反应。本发明所揭示的方法和由此产生的制剂只需注射一次，就能诱导包括 2 岁以下儿童在内的人产生伤寒免疫力，从而构成完整的疫苗接种计划。
• Manufacture of vaccines and compositions for the prevention of Salmonella infections
  申请人：Bharat Biotech International Limited

  公开号：US10702595B2

  公开（公告）日：2020-07-07

  Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.

  本发明公开了用于预防伤寒沙门氏菌的稳定共轭疫苗制剂，以及将伤寒沙门氏菌的Vi-多糖与作为载体蛋白的破伤风类毒素共轭的方法，这些方法可产生针对伤寒沙门氏菌引起的伤寒的更好的T依赖性免疫反应。本发明所揭示的方法和由此产生的制剂只需注射一次，就能诱导包括 2 岁以下儿童在内的人产生伤寒免疫力，从而构成完整的疫苗接种计划。
• Methods for the prevention of Salmonella infections
  申请人：Bharat Biotech International Limited

  公开号：US10758604B2

  公开（公告）日：2020-09-01

  Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.

  本发明公开了用于预防伤寒沙门氏菌的稳定共轭疫苗制剂，以及将伤寒沙门氏菌的Vi-多糖与作为载体蛋白的破伤风类毒素共轭的方法，这些方法可产生针对伤寒沙门氏菌引起的伤寒的更好的T依赖性免疫反应。本发明所揭示的方法和由此产生的制剂只需注射一次，就能诱导包括 2 岁以下儿童在内的人产生伤寒免疫力，从而构成完整的疫苗接种计划。
• A BACTERIAL VACCINE AND METHODS FOR MANUFACTURE THEREOF
  申请人：Bharat Biotech International Limited

  公开号：EP3035957B1

  公开（公告）日：2019-11-20
• BACTERIAL VACCINE AND METHODS FOR MANUFACTURE THEREOF
  申请人：Bharat Botech International Limited

  公开号：US20160206721A1

  公开（公告）日：2016-07-21

  Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi , and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi . The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.